Tabrecta® (capmatinib)

About Incyte

Founded in 2002 and headquartered in Wilmington, Delaware, Incyte has evolved from a small team of scientists into a leading global biopharmaceutical company with three core franchises. The company maintains a robust pipeline with ongoing clinical trials in dozens of disease areas and has been recognized as a top employer by Science Magazine for eight consecutive years. With over 1,000 research and clinical development employees, Incyte continues to advance breakthrough treatments under their mission to 'Solve On' for patients worldwide.

Therapeutic Areas